In a study published in the American Journal of Clinical Pathology, advanced flow cytometry demonstrated 98% in identifying acute leukaemia, showcasing its remarkable precision.

AFFIRM-1 targets enrollment of 330 adult patients with SAD at clinical sites in the United States (U.S.). It is a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial.

Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Sai Lomte, Tarun. (2025, June 02). Experts chart path to bring microbiome science into routine ...

Device delivers currents to the brain to restore activity usually lowered in depression patients Device delivers currents to the brain to restore activity usually lowered in depression patients ...

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder Provided by GlobeNewswire Apr 10, 2025, 12:25:00 PM ...

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory celebrating a decade at the forefront of genetic testing, today shared research on the value of both ...

Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform . Vancouver, Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND ...